Selected research
Industry Research
Nuclear Medicine Therapy Industry Research Report 2026
Market perspective
The global Nuclear Medicine Therapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Nuclear Medicine Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Nuclear Medicine Therapy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Nuclear Medicine Therapy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Nuclear Medicine Therapy include Aurobindo Pharma, China Isotope & Radiation, Curium Pharmaceuticals, International Isotopes, Jubilant Radiopharma, Lantheus, Mundipharma, Q BioMed and Bayer, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Nuclear Medicine Therapy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Nuclear Medicine Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nuclear Medicine Therapy Market by Company
Aurobindo Pharma
China Isotope & Radiation
Curium Pharmaceuticals
International Isotopes
Jubilant Radiopharma
Lantheus
Mundipharma
Q BioMed
Bayer
Dongcheng
Novartis
Nuclear Medicine Therapy Segment by Type
Lutetium-177
Radium-223
Iodine-131
Other
Nuclear Medicine Therapy Segment by Application
Bone Metastasis
Thyroid
Lymphoma
Other
Nuclear Medicine Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nuclear Medicine Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Lutetium-177
- Radium-223
- Iodine-131
- Other
Applications
- Bone Metastasis
- Thyroid
- Lymphoma
- Other
Companies covered
- Aurobindo Pharma
- China Isotope & Radiation
- Curium Pharmaceuticals
- International Isotopes
- Jubilant Radiopharma
- Lantheus
- Mundipharma
- Q BioMed
- Bayer
- Dongcheng
- Novartis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Nuclear Medicine Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Lutetium-177
- 2.2.3 Radium-223
- 2.2.4 Iodine-131
- 2.2.5 Other
- 2.3 Nuclear Medicine Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Bone Metastasis
- 2.3.3 Thyroid
- 2.3.4 Lymphoma
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Nuclear Medicine Therapy Breakdown Data by Type
- 3.1 Global Nuclear Medicine Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Nuclear Medicine Therapy Forecasted Market Size by Type (2027-2032)
4 Nuclear Medicine Therapy Breakdown Data by Application
- 4.1 Global Nuclear Medicine Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Nuclear Medicine Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Nuclear Medicine Therapy Market Perspective (2021-2032)
- 5.2 Global Nuclear Medicine Therapy Growth Trends by Region
- 5.2.1 Global Nuclear Medicine Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Nuclear Medicine Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 Nuclear Medicine Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 Nuclear Medicine Therapy Market Dynamics
- 5.3.1 Nuclear Medicine Therapy Industry Trends
- 5.3.2 Nuclear Medicine Therapy Market Drivers
- 5.3.3 Nuclear Medicine Therapy Market Challenges
- 5.3.4 Nuclear Medicine Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Nuclear Medicine Therapy Players by Revenue
- 6.1.1 Global Top Nuclear Medicine Therapy Players by Revenue (2021-2026)
- 6.1.2 Global Nuclear Medicine Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Nuclear Medicine Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Nuclear Medicine Therapy Head Office and Area Served
- 6.4 Global Nuclear Medicine Therapy Players, Product Type & Application
- 6.5 Global Nuclear Medicine Therapy Manufacturers Established Date
- 6.6 Global Nuclear Medicine Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Nuclear Medicine Therapy Market Size (2021-2032)
- 7.2 North America Nuclear Medicine Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Nuclear Medicine Therapy Market Size by Country (2021-2026)
- 7.4 North America Nuclear Medicine Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Nuclear Medicine Therapy Market Size (2021-2032)
- 8.2 Europe Nuclear Medicine Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Nuclear Medicine Therapy Market Size by Country (2021-2026)
- 8.4 Europe Nuclear Medicine Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Nuclear Medicine Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific Nuclear Medicine Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Nuclear Medicine Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Nuclear Medicine Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Nuclear Medicine Therapy Market Size (2021-2032)
- 10.2 South America Nuclear Medicine Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Nuclear Medicine Therapy Market Size by Country (2021-2026)
- 10.4 South America Nuclear Medicine Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Nuclear Medicine Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa Nuclear Medicine Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Nuclear Medicine Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Nuclear Medicine Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Aurobindo Pharma
- 12.1.1 Aurobindo Pharma Company Information
- 12.1.2 Aurobindo Pharma Business Overview
- 12.1.3 Aurobindo Pharma Revenue in Nuclear Medicine Therapy Business (2021-2026)
- 12.1.4 Aurobindo Pharma Nuclear Medicine Therapy Product Portfolio
- 12.1.5 Aurobindo Pharma Recent Developments
- 12.2 China Isotope & Radiation
- 12.2.1 China Isotope & Radiation Company Information
- 12.2.2 China Isotope & Radiation Business Overview
- 12.2.3 China Isotope & Radiation Revenue in Nuclear Medicine Therapy Business (2021-2026)
- 12.2.4 China Isotope & Radiation Nuclear Medicine Therapy Product Portfolio
- 12.2.5 China Isotope & Radiation Recent Developments
- 12.3 Curium Pharmaceuticals
- 12.3.1 Curium Pharmaceuticals Company Information
- 12.3.2 Curium Pharmaceuticals Business Overview
- 12.3.3 Curium Pharmaceuticals Revenue in Nuclear Medicine Therapy Business (2021-2026)
- 12.3.4 Curium Pharmaceuticals Nuclear Medicine Therapy Product Portfolio
- 12.3.5 Curium Pharmaceuticals Recent Developments
- 12.4 International Isotopes
- 12.4.1 International Isotopes Company Information
- 12.4.2 International Isotopes Business Overview
- 12.4.3 International Isotopes Revenue in Nuclear Medicine Therapy Business (2021-2026)
- 12.4.4 International Isotopes Nuclear Medicine Therapy Product Portfolio
- 12.4.5 International Isotopes Recent Developments
- 12.5 Jubilant Radiopharma
- 12.5.1 Jubilant Radiopharma Company Information
- 12.5.2 Jubilant Radiopharma Business Overview
- 12.5.3 Jubilant Radiopharma Revenue in Nuclear Medicine Therapy Business (2021-2026)
- 12.5.4 Jubilant Radiopharma Nuclear Medicine Therapy Product Portfolio
- 12.5.5 Jubilant Radiopharma Recent Developments
- 12.6 Lantheus
- 12.6.1 Lantheus Company Information
- 12.6.2 Lantheus Business Overview
- 12.6.3 Lantheus Revenue in Nuclear Medicine Therapy Business (2021-2026)
- 12.6.4 Lantheus Nuclear Medicine Therapy Product Portfolio
- 12.6.5 Lantheus Recent Developments
- 12.7 Mundipharma
- 12.7.1 Mundipharma Company Information
- 12.7.2 Mundipharma Business Overview
- 12.7.3 Mundipharma Revenue in Nuclear Medicine Therapy Business (2021-2026)
- 12.7.4 Mundipharma Nuclear Medicine Therapy Product Portfolio
- 12.7.5 Mundipharma Recent Developments
- 12.8 Q BioMed
- 12.8.1 Q BioMed Company Information
- 12.8.2 Q BioMed Business Overview
- 12.8.3 Q BioMed Revenue in Nuclear Medicine Therapy Business (2021-2026)
- 12.8.4 Q BioMed Nuclear Medicine Therapy Product Portfolio
- 12.8.5 Q BioMed Recent Developments
- 12.9 Bayer
- 12.9.1 Bayer Company Information
- 12.9.2 Bayer Business Overview
- 12.9.3 Bayer Revenue in Nuclear Medicine Therapy Business (2021-2026)
- 12.9.4 Bayer Nuclear Medicine Therapy Product Portfolio
- 12.9.5 Bayer Recent Developments
- 12.10 Dongcheng
- 12.10.1 Dongcheng Company Information
- 12.10.2 Dongcheng Business Overview
- 12.10.3 Dongcheng Revenue in Nuclear Medicine Therapy Business (2021-2026)
- 12.10.4 Dongcheng Nuclear Medicine Therapy Product Portfolio
- 12.10.5 Dongcheng Recent Developments
- 12.11 Novartis
- 12.11.1 Novartis Company Information
- 12.11.2 Novartis Business Overview
- 12.11.3 Novartis Revenue in Nuclear Medicine Therapy Business (2021-2026)
- 12.11.4 Novartis Nuclear Medicine Therapy Product Portfolio
- 12.11.5 Novartis Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst